Literature DB >> 19739071

Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study).

Dorien C Rijkaart1, Johannes Berkhof, Folkert J van Kemenade, Lawrence Rozendaal, René H M Verheijen, Saskia Bulk, Miriam E Herreilers, Wim M Verweij, Peter J F Snijders, Chris J L M Meijer.   

Abstract

We studied the effectiveness of high-risk human papillomavirus (hrHPV) triage for immediate colposcopy in women with borderline or mild dyskaryosis (BMD). In the Utrecht province of the Netherlands, women aged 30-60 years who participated in the regular cervical screening programme were offered hrHPV testing and cytology (intervention group) or cytology only (control group). In the intervention group (n = 337), women with BMD were immediately referred for colposcopy only if the sample was hrHPV positive. Women with a hrHPV negative test were advised to repeat cytology at 6 and 18 months and were referred for colposcopy if and when the repeat test result was positive (BMD or worse). In the control group (n = 329), referral of women with BMD was delayed until cytology was repeatedly positive at 6 or 18 months. The CIN3 detection rates were 10.7% (36/337) in the intervention group and 6.4% (21/329) in the control group (p = 0.047). Moreover, hrHPV triaging resulted in shorter time to diagnosis (154 vs. 381 days). Although the number of colposcopy referrals was 51.5% higher in the intervention group than in the control group, the medical costs per detected CIN3 were slightly lower ([euro] 4781 vs. [euro] 6235). If, in addition, hrHPV negative women had been referred back to routine screening at baseline, the CIN3 rate would have been 10.1% (34/337) and colposcopy rate would only have been 30.4% higher than in the control group. This study shows that hrHPV triaging of women with BMD is at least as effective for detecting CIN3 as repeat cytology, also when hrHPV negative women are referred back to routine screening.

Entities:  

Mesh:

Year:  2010        PMID: 19739071     DOI: 10.1002/ijc.24891

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Clinical validation of the cobas 4800 HPV test for cervical screening purposes.

Authors:  D A M Heideman; A T Hesselink; J Berkhof; F van Kemenade; W J G Melchers; N Fransen Daalmeijer; M Verkuijten; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

2.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Authors:  Hormuzd A Katki; Walter K Kinney; Barbara Fetterman; Thomas Lorey; Nancy E Poitras; Li Cheung; Franklin Demuth; Mark Schiffman; Sholom Wacholder; Philip E Castle
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

3.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Authors:  D C Rijkaart; V M H Coupe; F J van Kemenade; D A M Heideman; A T Hesselink; W Verweij; L Rozendaal; R H Verheijen; P J Snijders; J Berkhof; C J L M Meijer
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

4.  HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.

Authors:  D C Rijkaart; J Berkhof; F J van Kemenade; V M H Coupe; L Rozendaal; D A M Heideman; R H M Verheijen; S Bulk; W Verweij; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2012-01-17       Impact factor: 7.640

5.  Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing.

Authors:  M Kocken; J Berkhof; F J van Kemenade; J A Louwers; A Zaal; M A E Nobbenhuis; G Kenter; P J F Snijders; C J L M Meijer; T J M Helmerhorst
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

6.  HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.

Authors:  Cornelis Johannes Jacobus Huijsmans; Willemina Rosalia Rita Geurts-Giele; Cindy Leeijen; Hendrikus Lambertus Cornelius Maria Hazenberg; Jenneke van Beek; Carola de Wild; Johannes Cornelis van der Linden; Adrianus Johannes Christiaan van den Brule
Journal:  BMC Cancer       Date:  2016-11-28       Impact factor: 4.430

7.  Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma.

Authors:  Rong Wang; Robert W van Leeuwen; Aniek Boers; Harry G Klip; Tim de Meyer; Renske D M Steenbergen; Wim van Criekinge; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman
Journal:  Oncotarget       Date:  2016-12-06

8.  Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study.

Authors:  M H Uijterwaal; B I Witte; F J Van Kemenade; D Rijkaart; R Ridder; J Berkhof; G A M A Balfoort-van der Meij; M C G Bleeker; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.